However, human clinical trials are scarce
Beyond these major organs, the receptor turns up on cells of the immune system, including macrophages, lymphocytes, and invariant natural killer T cells, where it appears to exert anti-inflammatory effects
Researchers building long-term protocols should note that 4mg may become the standard entry-level prescribed dose once approval occurs, making current data at this level especially relevant for understanding what the future standard of care might look like
Targeting development of incretin-producing cells increases insulin secretion
GLP-1 secretion may be impaired in individuals with metabolic health concerns like insulin resistance, or type 2 diabetes
Semaglutide injection (Wegovy) and liraglutide (Saxenda) are FDA-approved specifically for chronic weight management and can be used in post-bariatric patients